NDC 50742-397-01 - Buprenorphine and Naloxone
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 50742-397
- Requested NDC
- 50742-397-01
- Package NDCs from labels
- 50742-397-01, 50742-397-30
- Manufacturer
- Redpharm Drug
- Effective date
- 2026-04-22
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Buprenorphine and Naloxone - Redpharm Drug | Redpharm Drug | 2026-04-22 | HUMAN PRESCRIPTION DRUG LABEL |
| ACESULFAME POTASSIUM - INGENUS PHARMACEUTICALS, LLC | DifGen Pharmaceuticals LLC | Aveva Drug Delivery Systems, Inc | INGENUS PHARMACEUTICALS, LLC | DifGen Pharmaceuticals LLC | Aveva Drug Delivery Systems, Inc | 2026-03-23 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 50742-397-01 | Buprenorphine and Naloxone | 1 in 1 POUCH | FILM | 1 | 6 | |
| 50742-397-30 | Buprenorphine and Naloxone | 30 in 1 CARTON | FILM | 30 | 6 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 50742-397-01 | EA - Each | 50742-397 | aa4c2b07-0699-49cf-8d69-6c63a89e993c | 1 | 2025-06-13 |
| 50742-397-30 | EA - Each | 50742-397 | 42327cd3-42ee-452c-af20-917e6d8eac80 | 1 | 2025-06-13 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Unit Dose Solutions, Inc. | 4f979409-f9a2-d3a2-e063-6394a90accd0 | 2026-04-16 | Warnings, Adverse reactions | 56W8MW3EN1 |
| CLENPIQ | SODIUM PICOSULFATE, MAGNESIUM OXIDE, AND ANHYDROUS CITRIC ACID | Ferring Pharmaceuticals Inc. | e95fff66-4ec0-4001-a727-33e66a5ec7d5 | 2026-04-15 | Warnings, Adverse reactions | XF417D3PSL |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Aveva Drug Delivery Systems Inc. | cb112448-49a1-4209-bcdb-7cfae6501f51 | 2026-04-07 | Warnings, Adverse reactions | ANDA212756 1307056 1307061 1010604 1010600 F850569PQR 56W8MW3EN1 |
| Sodium Citrate and Citric Acid | SODIUM CITRATE AND CITRIC ACID | Chartwell Governmental & Specialty RX, LLC | 58c24504-47de-487a-ab8d-18add155ea95 | 2026-04-07 | Adverse reactions | 1Q73Q2JULR |
| BUPRENORPHINE | BUPRENORPHINE | Bryant Ranch Prepack | cd0a90c6-32cc-4114-8573-86ac85503bdf | 2026-04-03 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine HCl and Naloxone HCl | BUPRENORPHINE AND NALOXONE | Bryant Ranch Prepack | 2aaad1a7-a0fd-4dd5-bb53-03afad8f10b9 | 2026-04-03 | Warnings, Adverse reactions | 56W8MW3EN1 |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | BluePoint Laboratories | 327004b0-560a-84d0-e063-6294a90aa743 | 2026-04-02 | Warnings | F850569PQR |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | INGENUS PHARMACEUTICALS, LLC | 4951ec29-609b-4836-b0e4-0d9c1d6ae6fe | 2026-03-23 | Warnings, Adverse reactions | ANDA212756 50742-364-01 50742-397-30 50742-397-01 50742-365-30 50742-364-30 50742-365-01 50742-398-30 50742-398-01 50742-364 50742-398 50742-365 50742-397 50742039701 1307056 1307061 1010604 1010600 4db0df39-ce1f-bb08-e063-6294a90a3a4a 4951ec29-609b-4836-b0e4-0d9c1d6ae6fe F850569PQR 56W8MW3EN1 |
| Buprenorphine HCl | BUPRENORPHINE HCL | REMEDYREPACK INC. | 69a647c0-bc09-4ee2-aeb3-ef286caf25e5 | 2026-03-23 | Warnings, Adverse reactions | 56W8MW3EN1 |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | HF Acquisition Co. LLC. DBA HealthFirst | 4d66b96a-acbb-2292-e063-6294a90af788 | 2026-03-19 | Warnings, Adverse reactions | F850569PQR |
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Clinical Solutions Wholesale, LLC | 99a5b62f-bc08-44f4-abb8-300520d2162a | 2026-03-06 | Warnings, Adverse reactions | 56W8MW3EN1 |
| BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Clinical Solutions Wholesale, LLC | 8f2b94dc-f42f-45d5-8274-9e748ec20ef0 | 2026-03-05 | Warnings, Adverse reactions | 56W8MW3EN1 |
| REZENOPY | NALOXONE HCL | Scienture LLC | 5bb502aa-014f-4a36-8972-42a9439168fe | 2026-03-03 | Warnings, Adverse reactions | F850569PQR |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | Henry Schein, Inc | bd65e3fe-cd7a-4855-8f55-8cc3a0921ccc | 2026-03-02 | Warnings, Adverse reactions | F850569PQR |
| buprenorphine hydrochloride | BUPRENORPHINE HYDROCHLORIDE | PAI Holdings, LLC dba PAI Pharma | 442831cf-9636-433a-9a12-e9a8cd31f72a | 2026-02-28 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | PAI Holdings, LLC dba PAI Pharma | d5b011ef-f1be-47f2-8f8b-07553f36193c | 2026-02-28 | Warnings, Adverse reactions | F850569PQR 56W8MW3EN1 |
| Kidnex IV | GINKGO BILOBA, ALPHA-KETOGLUTARICUM ACIDUM, CITRICUM ACIDUM, FUMARICUM ACIDUM, MALICUM ACIDUM, PYRUVIC ACID, SUCCINICUM ACIDUM, ARGENTUM METALLICUM, AURUM METALLICUM, CUPRUM METALLICUM, GERMANIUM SESQUIOXIDE, MERCURIUS VIVUS, NUX VOMICA, KIDNEY (SUIS), LYMPH NODE (SUIS), NAPHTHOCHINONUM, NATRUM OXALACETICUM, PHOSPHORUS, URINARY BLADDER (SUIS), ACONITICUM ACIDUM, CIS- | Energique, Inc. | 23de6b8e-7622-4ba6-89f7-37bd151687e2 | 2026-02-26 | Warnings | XF417D3PSL |
| Tricitrates | TRICITRATES | Chartwell Governmental & Specialty RX, LLC. | c4ff0407-3930-4c48-afd4-d2cb3e1b18f4 | 2026-02-25 | Warnings, Adverse reactions | 1Q73Q2JULR |
| Leader Extra Strength Effervescent Antacid and Pain Reliever | ASPIRIN, CITRIC ACID, SODIUM BICARBONATE | Cardinal Health | c5d7bf5f-3e59-52f2-e053-2a95a90a4a00 | 2026-02-25 | Warnings | XF417D3PSL |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Redpharm Drug | 300ae3d0-464c-d0be-e063-6294a90a7f9d | 2026-02-21 | Warnings, Adverse reactions | 1010600 56W8MW3EN1 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.